Scarica l'app Stockscreener
2.02
30.82%
-0.90
Dopo l'orario di chiusura:
2.07
0.05
+2.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Precedente Chiudi:
$2.92
Aprire:
$2.91
Volume 24 ore:
2.50M
Relative Volume:
4.37
Capitalizzazione di mercato:
$119.96M
Reddito:
$30.91M
Utile/perdita netta:
$-74.28M
Rapporto P/E:
-1.658
EPS:
-1.2183
Flusso di cassa netto:
$-86.15M
1 W Prestazione:
-42.29%
1M Prestazione:
-60.93%
6M Prestazione:
-59.03%
1 anno Prestazione:
-55.51%
Intervallo 1D:
$1.99
$2.91
Intervallo di 1 settimana:
$1.79
$3.62
Portata 52W:
$1.79
$7.61
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Nome
Foghorn Therapeutics Inc
Settore
Industria
Telefono
617-586-3100
Indirizzo
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
2.02 | 207.85M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Ripresa | Jefferies | Buy |
| 2025-12-18 | Iniziato | BTIG Research | Buy |
| 2025-11-07 | Iniziato | Guggenheim | Buy |
| 2025-09-17 | Ripresa | B. Riley Securities | Buy |
| 2025-04-23 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Iniziato | B. Riley Securities | Buy |
| 2024-09-03 | Iniziato | Jefferies | Buy |
| 2024-08-19 | Iniziato | Evercore ISI | Outperform |
| 2023-03-28 | Iniziato | BofA Securities | Buy |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-17 | Iniziato | Cowen | Outperform |
| 2020-11-17 | Iniziato | Goldman | Buy |
| 2020-11-17 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-17 | Iniziato | Wedbush | Outperform |
Mostra tutto
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt - Investing.com Canada
Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation By Investing.com - Investing.com Canada
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs - Barron's
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift - Investing.com
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift By Investing.com - Investing.com Canada
Why Is Foghorn Therapeutics Stock Tumbling Today?Foghorn Therapeutics (NASDAQ:FHTX) - Benzinga
Foghorn and Lilly Halt FHD-909 After Phase 1 Data - Minichart
Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review - Yahoo Finance
FHTX Stock Slides As Traders Focus On Cash Runway And Charts - StocksToTrade
FHTX Stock Slides As Traders Eye Key Support Levels - timothysykes.com
Why is Foghorn Therapeutics stock plummeting today? By Investing.com - Investing.com Canada
Foghorn Therapeutics Announces Major Strategic Reprioritization, Layoffs - TipRanks
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug - Yahoo Finance
Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha
Foghorn Therapeutics Provides Update On Fhd-909 And Strategic Priorities - TradingView
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities - GlobeNewswire
Enterprise value to EBITDA forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Citizens reiterates Foghorn Therapeutics stock rating on trial data By Investing.com - Investing.com Nigeria
Citizens reiterates Foghorn Therapeutics stock rating on trial data - Investing.com
Foghorn Therapeutics (FHTX) Slips 2.17% to $5.87 as Shares Approach Key Support ZoneStock Buy Zone - dars.gov.et
B. Riley Securities Initiates a Buy Rating on Foghorn Therapeutics (FHTX) - The Globe and Mail
Price to book forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Precision Trading with Foghorn Therapeutics Inc. (FHTX) Risk Zones - Stock Traders Daily
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet - Yahoo Finance
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Foghorn Therapeutics (FHTX) Slips 3.5% as Shares Test Key Support Near $5.95Low Vol Factor - vinanet.vn
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - Kalkine
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Foghorn Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FHTX | US3441741077 - marketscreener.com
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
HC Wainwright Issues Negative Outlook for FHTX Earnings - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Hold - MarketBeat
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail
BTIG Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Discipline and Rules-Based Execution in FHTX Response - Stock Traders Daily
Foghorn Therapeutics (NASDAQ:FHTX) Issues Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
Foghorn Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics advances FHD-909 with Lilly and launches oral immunology program in Q2 update - Traders Union
Foghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingView
Lilly deal lifts Foghorn Therapeutics (Nasdaq: FHTX) Q2 2026 revenue and cuts loss - Stock Titan
Foghorn’s lung cancer trial advances; IND targeted for 2027 - stocktitan.net
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - Investing News Network
Foghorn Therapeutics (FHTX) Jumps 5.4% as Biotech Stock Approaches Key Resistance at $5.10IV Expansion Alert - careplusvn.com
Foghorn Therapeutics (FHTX) Rises 1.77% as Shares Hold Above Key Support at $4.38Dividend Arbitrage - dars.gov.et
Foghorn Therapeutics (FHTX) Slides 4.4% to $4.53, Approaching Key Support LevelOrder Block - vinanet.vn
Foghorn Therapeutics Inc Azioni (FHTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):